Objective-Low high-density lipoprotein (HDL) cholesterol levels are frequently observed in familial hypercholesterolemia (FH) and might be associated with functional alterations of HDL particles that may influence their efficaciousness in the reverse cholesterol transport pathway. Methods and Results-We evaluated key steps of the reverse cholesterol transport, ie, cellular free cholesterol efflux, cholesteryl ester transfer protein-mediated cholesteryl ester (CE) transfer from HDL to apolipoprotein B-containing lipoproteins, and hepatic HDL-CE uptake, in patients displaying FH (nϭ12) and in healthy normolipidemic control subjects (nϭ12). Large HDL2 particles isolated from FH patients displayed a reduced capacity to mediate free cholesterol efflux via both scavenger receptor-BI-and ABCG1-dependent pathways. A significant inverse relationship between scavenger receptor-BI-dependent HDL2 efflux capacity and carotid intima-media thickness (rϭϪ0.473; Pϭ0.0186), as well as between ABCG1-dependent HDL2 efflux capacity and carotid intima-media thickness (rϭϪ0.485; Pϭ0.0212), was detected. We also observed an elevated cholesteryl ester transfer protein-mediated CE transfer from HDL2 and HDL3 particles to low-density lipoprotein and a reduced capacity of HDL particles to deliver CEs to the liver. Conclusion-We demonstrated that the centripetal movement of cholesterol from peripheral tissues, including the vessel wall, to feces is defective in FH, thereby emphasizing its atherogenicity. (Arterioscler Thromb Vasc Biol. 2011;31:1675-1681.) 
F amilial hypercholesterolemia (FH) is a common inherited dominant autosomal disorder caused by mutations in the gene encoding the low-density lipoprotein (LDL) receptor. 1 These mutations lead to a reduced number of functional LDL receptors, resulting in diminished cellular uptake of LDL particles, LDL accumulation, and increased plasma levels of total cholesterol, LDL cholesterol, and premature atherosclerosis. 2, 3 Within the arterial wall, macrophages take up modified LDL through a variety of scavenger receptors, mainly scavenger receptor (SR)-A and CD36, accumulate cholesteryl esters (CEs), and are progressively converted into lipid-rich foam cells that represent the hallmark of the atherosclerotic plaque. 4 Excess cholesterol in macrophages is eliminated via the process of reverse cholesterol transport (RCT), a pathway by which cholesterol from peripheral tissues is transported to the liver for biliary excretion. 5 During the past few years, the atheroprotective role of RCT has been clearly demonstrated in humans. 6 The first step in this pathway is the efflux of cholesterol from cells to extracellular acceptors, such as high-density lipoprotein (HDL) and apolipoprotein AI (apoAI). Cellular cholesterol efflux to lipid-free or lipid-poor apoAI occurs through a transporter belonging to the ATP binding cassette (ABC) family, ABCA1, 7 whereas free cholesterol efflux to mature HDL particles involves both ABCG1 8 and SR-BI. 9 The low HDL cholesterol levels frequently observed in FH patients represent an independent risk factor for the premature development of cardiovascular disease. However, the metabolic basis underlying this low-HDL phenotype has not been entirely elucidated to date. An increased apoAI fractional catabolic rate associated with reduced apoAI synthesis has been previously reported. 10, 11 It has also been suggested that APOE gene polymorphism might affect HDL levels in heterozygous FH patients. 12 Antiatherogenic properties of HDL are frequently compromised in metabolic diseases associated with a high cardiovascular risk. 13 It has been reported that FH patients with elevated plasma triglyceride levels (Ͼ1.5 g/L) display HDL3 particles that possess a reduced antiinflammatory capacity and a decreased ability to promote cholesterol efflux from macrophages in comparison with control subjects. 14 In this context, we have recently reported that the major HDL subfractions, HDL2 and HDL3, exhibit functional anomalies in patients displaying a mixed hyperlipidemia that significantly alter efficaciousness of the RCT. 15 To date, only a few studies have investigated the mechanism of RCT in FH patients. Compared with normolipidemic subjects, both cholesteryl ester transfer protein (CETP) plasma levels and activity are elevated in FH patients. 16 -18 In addition, CE transfer from HDL is preferentially enhanced toward small dense LDL particles. 17 In consequence, CETP appears to play a proatherogenic role in FH by increasing the cholesterol load in apoBcontaining lipoproteins. In the present study, we evaluated whether a potential dysfunction of HDL particles, in particular in their capacity to mediate key steps of the RCT pathway, might contribute significantly to accelerate atherosclerosis in FH patients.
Methods

Patients
Twelve patients aged 13 to 29 years and displaying a FH typical of the type IIa lipid phenotype (5 men and 7 women) were selected for the study. Twelve healthy normolipidemic subjects matched for age (mean, 23Ϯ0.6 years) and sex (5 men, 7 women) served as control subjects. Major clinical and biological characteristics of FH patients before and after cholesterol-lowering therapy and of normolipidemic control subjects are presented in Supplemental Table I , available online at http://atvb.ahajournals.org. Carotid and femoral artery atherosclerosis was determined by high-resolution B-mode ultrasound as previously described. 19 The study was performed in accordance with the ethical principles set forth in the Declaration of Helsinki. Written informed consent was obtained from all patients.
Lipoprotein Fractionation and Pre-␤ HDL Quantification
Plasma lipoproteins were isolated from plasma by density gradient ultracentrifugation in a Beckman SW41 Ti rotor at 40 000 rpm for 48 hours in a Beckman XL70 at 15°C as previously described. 20 The quantification of pre-␤-HDL in plasma was performed as previously described. 21 The amount of pre-␤-HDL was expressed as the percentage of total apoAI (relative concentration) and as absolute concentration (mg/L apoAI) by multiplying its percentage by plasma apoAI levels. Total HDL mass was calculated by adding plasma concentrations of HDL2, HDL3, and pre-␤-HDL.
Lipid and Protein Analysis
The lipid contents of plasma and isolated lipoprotein fractions, total protein, apoAI, apoAII, and apoB were quantified with an Autoanalyzer ( Konelab 20) . Details are given in the Supplemental Methods. Analysis of molecular species of phosphatidylcholine (PC) and sphingomyelin (SM) in HDL subfractions was measured by highperformance liquid chromatography as previously described. 22
Free Cholesterol Efflux Assays
Lipid efflux assays using Fu5AH, Raw264.7, CHO-K1, Chinese hamster ovary (CHO)-human ABCG1, human THP-1 monocytic cells, and human monocyte-derived macrophages were performed as described previously. 15, 23, 24 More details are given in the Supplemental Methods.
Statistical Analysis
All data are presented in meanϮSE. Experimental data were analyzed using the SAS software (SAS/STAT User's Guide, version 8, SAS Institute Inc., Cary, NC). Differences between patients displaying FH and healthy normolipidemic control subjects were analyzed using Mann-Whitney nonparametric analysis. The results were considered to be statistically significant at PϽ0.05.
Details of procedures for determination of endogenous plasma CETP activity, plasma phospholipid transfer protein (PLTP) activity, in vitro determination of selective uptake of HDL-CE, and in vivo metabolic studies are given in the Supplemental Methods.
Results
Plasma Lipid and Apolipoprotein Levels
Despite aggressive cholesterol-lowering therapy, type IIa hypercholesterolemic patients still displayed marked elevation in plasma total cholesterol (ϩ140%; PϽ0.0001) and LDL cholesterol (ϩ238%; PϽ0.0001) levels in comparison with healthy normolipidemic control subjects. FH patients were also characterized by significantly reduced plasma HDL cholesterol (Ϫ54%; PϽ0.0001) levels ( Supplemental Table  I ). In addition, as shown in Table 1 , treated FH patients still developed atherosclerosis. Indeed, mean carotid intimamedia thickness (CIMT) for FH patients was 0.78Ϯ0.12 mm (ranging from 0.44 to 1.80), whereas mean CIMT for normolipidemic control subjects was 0.47Ϯ0.02 mm (ranging from 0.39 to 0.56). In addition, 3 of the 12 IIa hypercholesterolemic patients, representing 25% of our study population, displayed arterial plaques.
Quantification of pre-␤-HDL particles revealed that the relative concentration of pre-␤-HDL particles, expressed as a percentage of apoAI, was significantly increased in type IIa hypercholesterolemic patients in comparison with normolipidemic subjects (12.1Ϯ1.6% and 5.6Ϯ0.4% in FH and controls subjects, respectively; PϽ0.001). In addition, absolute plasma concentrations of pre-␤-HDL particles appeared significantly higher in FH patients relative to controls (119.2Ϯ16.9 and 81.6Ϯ7.4 mg/L apoAI in FH and controls subjects, respectively; PϽ0.05).
Characterization of Plasma HDL Subspecies
The total HDL mass concentration was significantly lower (Ϫ25%; PϽ0.0002) in type IIa hypercholesterolemic patients compared with normolipidemic controls (277.9Ϯ16.9 and 374.2Ϯ11.0 mg/dL in FH and control subjects, respectively). This difference reflected a significantly lower (Ϫ34%; PϽ0.001) total plasma HDL2 (133.3Ϯ7.1 and 201.1Ϯ13.3 mg/dL in FH and control subjects, respectively), as well as a reduced (Ϫ20%; PϽ0.0003) plasma concentration of HDL3 (132.7Ϯ4.5 and 164.9Ϯ3.8 mg/dL in FH and control subjects, respectively) in FH patients compared with normolipidemic controls. The major HDL subfractions, ie, HDL2 and HDL3, from type IIa hypercholesterolemic patients were distinct in their chemical composition compared with their counterparts in normolipidemic control subjects ( Supplemental  Table II ). Indeed, we observed an increase in HDL2-CE content (ϩ12%; PϽ0.008) in type IIa patients compared with normolipidemic subjects. In addition, both HDL2 and HDL3 subfractions from type IIa patients were significantly depleted in phospholipids (HDL2: Ϫ18%, Pϭ0.0001; HDL3: -10%, PϽ0.02) compared with their normolipidemic counterparts. To further investigate the observed difference in the HDLphospholipids content between FH and controls subjects, we identified molecular phospholipid species in HDL2 and HDL3 subfractions ( Table 2) . Interestingly, we observed a significant reduction in PC content in both HDL2 (Ϫ25%; PϽ0.02) and HDL3 (Ϫ13%; PϽ0.05) from FH patients compared with controls, whereas no modification in the SM content was detected in HDL particles between the 2 groups of subjects. The reduction in HDL-PC content resulted primarily from a significant decrease in PC 16:0/18:2 (Ϫ37% and Ϫ28%, in HDL2 and HDL3, respectively; PϽ0.007) and in PC 18:0/18:2 (Ϫ23% and Ϫ24%, in HDL2 and HDL3, respectively; PϽ0.03). In consequence, the SM/PC ratio was significantly increased in both HDL2 (ϩ28%; PϽ0.02) and HDL3 (ϩ21%; PϽ0.02) from type IIa hypercholesterolemic patients in comparison with their counterparts from healthy normolipidemic subjects.
Determination of Cellular Free Cholesterol Efflux
Plasma Efflux Capacities
To determine whether quantitative and qualitative alterations observed on HDL particles from FH patients might influence the capacity of whole plasma to mediate the cellular free cholesterol efflux, we used three other cellular models, each representative of a specific cholesterol efflux pathway ( Supplemental Table III ).
HDL Efflux Capacities
As shown in Figure 1 , HDL2 particles obtained from hypercholesterolemic plasmas displayed a markedly reduced capacity to mediate cholesterol efflux through both SR-BI (Ϫ50%; PϽ0.0001; Figure 1A ) and ABCG1 (Ϫ21%; Pϭ0.0009; Figure 1B ) compared with their counterparts 
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isolated from normolipidemic control plasmas. In addition, we observed that the capacity of HDL3 particles to mediate cellular free cholesterol efflux via the SR-BI pathway was reduced significantly in FH patients (Ϫ24%; PϽ0.0001; Figure 1A ), whereas those via the ABCG1 pathway were not significantly different between the 2 subject groups ( Figure  1B) . Similar results were obtained when fractional cholesterol efflux to HDL particles was standardized on HDL-apoAI concentrations (data not shown). We then evaluated the capacity of HDL particles to mediate cellular free cholesterol efflux from human cholesterol-loaded THP-1 macrophages ( Figure 1C ). We observed that HDL2 particles isolated from hypercholesterolemic plasmas displayed a significantly reduced capacity for cholesterol efflux from human-like macrophages (Ϫ27%; Pϭ0.0006) compared with HDL2 particles from normolipidemic control subjects, whereas those of HDL3 were not altered. It is of particular interest that our present study reveals an association between efflux capacity of large HDL2 particles and premature development of atherosclerosis, as shown by a significant inverse relationship between SR-BI-dependent HDL2 efflux capacity and CIMT (rϭϪ0.473; Pϭ0.0186), as well as between ABCG1-dependent HDL2 efflux capacity and CIMT (rϭϪ0.485; Pϭ0.0212). In addition, we also observed an association between SR-BI dependent efflux capacity of HDL3 particles and CIMT; however, this relationship did not reach statistical significance (rϭϪ0.388; Pϭ0.0606).
Macrophage Efflux Capacities
To evaluate whether macrophages isolated from hypercholesterolemic patients might display an alteration in their capacity to promote cholesterol efflux, we performed cholesterol efflux assays using human monocyte-derived macrophages isolated from FH and normolipidemic control subjects in the presence of various extracellular cholesterol acceptors (Supplemental Figure) . We observed that human monocytederived macrophages isolated from FH patients or from control subjects displayed an equivalent capacity to promote cholesterol efflux to either lipid free apoAI, isolated HDL particles (HDL2 or HDL3), or 40-fold diluted plasma, indicating that SR-BI-, ABCA1-, or ABCG1-mediated efflux, as well as the overall efflux capacity of macrophages from FH patients, was not impaired.
Determination of CE and Phospholipid Transfer Rates
Plasma CETP activity, expressed as a percentage of CE transferred from HDL to apoB-containing lipoproteins, was significantly increased (ϩ68%; PϽ0.0001) in FH patients compared with CE transfer activity determined in healthy normolipidemic control subjects (55.7Ϯ1.8% and 33.2Ϯ3.7% in FH and controls, respectively). This increase resulted primarily from a significant 3.5-fold increase (PϽ0.0001) in the rate of CE transfer from HDL to LDL, whereas rates of CE transfer from HDL to very low density lipoproteinϩintermediate density lipoprotein were not significantly distinct between FH patients and control subjects (Supplemental Table IV ). Expression of CE mass transferred from HDL to LDL as a function of plasma LDL concentration allows us to estimate the capacity of LDL particles to accept CE from HDL. We observed that the capacity of LDL particles to accept CE from HDL was not significantly different between the 2 groups (13.9Ϯ2.1 and 10.7Ϯ0.1 g CE ⅐ h Ϫ1 ⅐ ml Ϫ1 LDL in FH patients and controls, respectively). Consistent with this latter observation, total CE transfer rates from HDL to apoB-containing lipoproteins were significantly correlated with plasma LDL levels (rϭ0.908; PϽ0.0001).
In addition, CE transfer rates from both HDL2 and HDL3 were considerably increased (2-fold and 5-fold from HDL2 and HDL3, respectively) in FH patients compared with normolipidemic controls. Interestingly, in normolipidemic subjects, HDL2 particles represented the major CE donor and accounted for 61% of the total CE transferred from HDL. By contrast, in FH patients, HDL3 particles appeared to be the major CE donor, accounting for 58% of the total CE transferred from HDL.
Plasma PLTP activity was significantly decreased (Ϫ37%; Pϭ0.001) in FH patients compared with PLTP activity determined in healthy normolipidemic control subjects (25.2Ϯ1.8 and 40.0Ϯ3.2 pmol transferred/min in FH and controls, respectively).
In Vitro Determination of Selective HDL-CE Uptake
The capacity of HDL particles isolated from type IIa or from normolipidemic subjects to deliver CEs to hepatic cells was evaluated in vitro using 2 distinct cellular models of human origin (HepG2) and of murine origin (Fu5AH) (Figure 2 ). HDL particles from FH patients displayed a significantly reduced (PϽ0.0002) capacity to deliver CE to hepatic cells compared with those isolated from normolipidemic subjects (Ϫ45% and Ϫ50% in Fu5AH and HepG2 cells, respectively).
In Vivo Determination of HDL Capacity to Promote RCT
The capacity of HDL particles isolated from type IIa or from normolipidemic subjects to deliver CEs to the liver was evaluated in vivo in low-density lipoprotein receptor (ldlr)ϩ/ϩ and ldlrϪ/Ϫ mice (Figure 3 ). Following injection, plasma clearance of radioactivity was similar for labeled HDL particles isolated from the two subject groups ( Figure  3A and 3B) . In vivo, liver uptake of radioactive tracer derived from HDL particles was significantly reduced in both ldlrϩ/ϩ mice (Ϫ38%; Pϭ0.0109) and ldlrϪ/Ϫ mice (Ϫ48%; Pϭ0.004) following injection of HDL particles isolated from type IIa patients compared with those from normolipidemic control subjects ( Figure 3C ). In addition, quantification of radioactivity excreted in feces revealed that HDL particles from FH patients displayed a significantly reduced capacity for HDL-mediated RCT to feces compared with HDL particles from normolipidemic control subjects ( Figure 3D ).
Our in vivo and in vitro observations are consistent in suggesting that HDL particles formed in FH patients displayed a defective capacity to mediate selective hepatic uptake of CE to the liver, leading to a reduced cholesterol elimination from the body. Indeed, it is important to keep in mind that mice do not have CETP, and thus SR-BI represents the unique way for hepatic HDL-CE uptake, whereas in humans, even in FH patients, alternative routes exist, such as via LDL related receptor-1 and heparan sulphate proteoglycan following intravascular redistribution of CEs through the action of CETP.
Discussion
In the present study, we demonstrated that FH is associated with quantitative and qualitative modifications of HDL particles that significantly alter their functions in the RCT pathway. Indeed, we observed reduced plasma HDL2 and HDL3 levels in FH patients compared with controls. These quantitative modifications occurred concomitantly with a reduction in the capacity of large HDL2 particles to mediate cellular free cholesterol efflux via both SR-BI and ABCG1 pathways. In addition, our study reveals for the first time an inverse relationship between HDL efflux capacity and development of atherosclerosis in FH patients. We also observed an elevated CETP-mediated CE transfer from HDL2 and HDL3 particles to LDL and a reduced capacity of HDL particles to deliver CEs to the liver for cholesterol excretion. Taken together, these observations demonstrate that the centripetal movement of cholesterol from peripheral tissues to feces is defective in FH. Our present observations strengthened a very recent study showing that patients with coronary artery disease displayed an impaired efflux capacity of HDL by using an ex vivo measurement system. 25 However, our present work adds significantly to this integrated/functional approach by addressing not only the cholesterol efflux capacity of plasma HDL but also the CETP-mediated CE transfer and the hepatic HDL-CE uptake.
We detected a significant increase in pre-␤-HDL particle levels in plasma from FH patients compared with normolipidemic controls. This observation is entirely consistent with previous studies showing increased levels of pre-␤1-HDL particles in coronary artery disease and in metabolic disorders, such as hypercholesterolemia and hypertriglyceridemia, 26 -28 or increased levels of pre-␤-HDL concentrations in obese patients. 29 Both CETP and PLTP have been shown to favor intravascular remodeling of HDL particles through different mechanisms. Indeed, CETP involves the conversion of large HDL particles into pre-␤ HDL, whereas PLTP favors the formation of both larger HDL and smaller HDL particles similar to pre-␤ HDL. 30 Thus, it is likely that the increased levels of pre-␤ HDL observed in FH patients in this study primarily reflect the predominant action of CETP.
It has been previously demonstrated that ABCA1dependent efflux is closely related to plasma pre-␤-HDL levels. 21 An increased capacity of whole plasma to mediate free cholesterol efflux via an ABCA1-dependent mechanism was therefore expected in FH patients. However, we observed a slight but not significant increase (ϩ15%) in the ABCA1- dependent efflux capacity of plasma from FH patients compared with normolipidemic controls. Both apoAI synthesis and the fractional catabolic rate of apoAI are altered in hypercholesterolemia. Indeed, it has been previously demonstrated that apoAI production is reduced whereas the fractional catabolic rate of apoAI is accelerated in FH patients compared with control subjects. 11 Because ABCA1 is known to mediate the export of cellular cholesterol to both lipid-free apoAI and to pre-␤-HDL particles, it is likely that in FH patients, ABCA1-dependent cellular cholesterol efflux to free apoAI is reduced but concomitantly increased toward pre-␤-HDL, resulting in an overall normal capacity of whole plasma to mediate cellular cholesterol efflux via the ABCA1 pathway. As mentioned above ABCA1 is responsible for the initial lipidation of apoAI and thus represents a critical molecule that regulates the initial step of the RCT pathway. Our observations might also suggest that levels of lipid free apoAI control ABCA1-dependent cholesterol efflux in a more efficient manner than those of pre-␤-HDL.
In agreement with earlier studies, we observed here that CETP-mediated CE transfer from HDL to LDL is accelerated in FH patients compared with normolipidemic control subjects. 16, 17 This increase in plasma CETP activity is associated with an increase both in CETP mass concentration 18 and in the number of lipoprotein acceptors, mainly LDL particles. 17 Consistent with that observation, LDL particles isolated from FH patients displayed a significant enrichment in their CE content (Supplemental Table V ).
The reduced capacity of HDL2 particles isolated from FH patients to mediate cellular cholesterol efflux via the SR-BI and ABCG1 pathways is entirely consistent with the observed modifications in lipid content, and more precisely, in phospholipid content, of HDL particles. It is well established that SR-BI-and ABCG1-dependent efflux preferentially involves large HDL particles and occurs in a phospholipid-dependent manner. 31, 32 In addition, PC represents an important phospholipid in HDL particles that determines the magnitude of cellular cholesterol efflux. 32, 33 Moreover, in good agreement with our present observations, it has recently been demonstrated that specifically increasing PC content in HDL particles leads to improve cholesterol efflux from SR-BIoverexpressing cells, as well as from human THP-1 cholesterol-loaded macrophages. 34 SR-BI mediates bidirectional flux of cholesterol between cell membranes and plasma lipoproteins. On the one hand, SR-BI is responsible for selective HDL lipid uptake in various tissues, including the liver, and on the other hand, SR-BI can mediate free cholesterol efflux from peripheral cells to HDL acceptors. Our data indicate that the reduction of both hepatic HDL-CE uptake and cellular free cholesterol efflux to HDL particles may contribute significantly to development of premature atherosclerosis in FH. The determinant atheroprotective role of SR-BI through its action on HDL-lipid uptake is well established, and so far SR-BI represents the only receptor that has been demonstrated to mediate selective HDL-CE uptake. The first human genetic variant of SR-BI has recently been reported, strengthening the major contribution of SR-BI in hepatic HDL-CE uptake. 35 However, we cannot exclude the possibility that another receptor, as yet unidentified, might contribute to HDL-CE uptake in addition to SR-BI. Nevertheless, the implication of such a receptor likely represents a minor contribution in this mechanism. By contrast, the contribution of SR-BI to free cholesterol efflux from macrophages to HDL for protection against atherosclerosis in humans remains controversial. In this context, it is relevant to consider that SR-BI/CD36 and LIMPII analogous-1 is highly expressed in fully differentiated human macrophages and has recently been shown to contribute significantly to the elimination of free cholesterol from cholesterol-loaded human macrophages. 24 Our present observations allow us to propose an integrated mechanism of the RCT pathway in patients displaying FH (Figure 4) . Key steps of the RCT, ie, cellular free cholesterol efflux, CETP-mediated CE transfer between plasma lipoproteins, and hepatic CE delivery, are altered in type IIa patients compared with the normolipidemic situation. Indeed, the capacity of HDL particles to mediate free cholesterol from peripheral cells with subsequent CE delivery to the liver is impaired. The CE transfer rates from HDL to LDL are accelerated as a result of an increase in the circulating number of LDL particles. The elevated CETP-mediated CE transfer from HDL to LDL favors the formation of CE-enriched LDL particles. In conclusion, we have demonstrated in this study that HDL particles in patients displaying FH are dysfunctional in their capacity to mediate RCT, thus further enhancing the progression of atherosclerosis in these subjects. Interestingly, partial CETP inhibition has been shown to normalize defective antiatherogenic functions of HDL particles, and notably their capacity to deliver CE to the liver and to mediate cellular free cholesterol efflux via both SR-BI and ABCG1 pathways, in type IIb hyperlipidemia. 15 Together, these observations strongly support the contention that the normalization of HDL functions may constitute a promising strategy in the treatment of FH patients to restore a physiological removal of cholesterol from peripheral tissues, including the arterial wall, and to favor the direct return of cholesterol to the liver. 
